<DOC>
	<DOCNO>NCT00584987</DOCNO>
	<brief_summary>We hypothesize daily use oxymetazoline cause significant rhinitis medicamentosa combination fluticasone furoate plus oxymetazoline lead faster relief nasal congestion secondary perennial allergic rhinitis use fluticasone furoate alone .</brief_summary>
	<brief_title>Intranasal Steroids Oxymetazoline Allergic Rhinitis</brief_title>
	<detailed_description>We perform 6-week , 4-group , parallel , randomized , double-blind , double-dummy , clinical trial 60 patient perennial allergic rhinitis . After initial screen allergy questionnaire skin puncture test confirm allergic response perennial allergen ( cat , dog , dust mite , indoor mold ) , qualified individual randomize 1 4 treatment group . The 4 group receive follow treatment : placebo , OXY ( 0.05 % , 2 puff nostril every evening ) , FF nasal spray ( 110 mg per day ) , FF nasal spray plus OXY ( FF/OXY ) . All participant receive 2 nasal spray night , 1 spray contain FF placebo , oxymetazoline placebo . The nasal spray label participant code number , investigator assign participant sequential randomized fashion study code number block 4 . Dropouts replace 60 subject randomize . Replacement subject assign next sequential treatment . Thus , number subject group exactly 15 . Eligible participant complete Rhinitis Quality Life Questionnaire ( RQLQ ) underwent measurement nasal volume acoustic rhinometry start study . Participants instructed keep diary daily symptom , nasal peak inspiratory flow ( NPIF ) meter reading , medication use study ; rescue medication allow . The severity sneezing , rhinorrhea , nasal congestion , symptom record morning ( reflective symptom overnight ) evening ( reflective daytime symptom ) 0 3 scale . Intake study medication perform daily , night , record symptom NPIF value . Subjects return nasal laboratory every 2 week total 4 week review symptom diary , replacement medication , performance acoustic rhinometry , completion RQLQ . After fourth week , participant stop treatment , return medication , continue clinical trial 2 additional week . During time , maintain symptom diary NPIF measurement twice daily . At end 2-week period , participant return nasal laboratory perform final acoustic rhinometry , complete RQLQ survey , return diary .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<criteria>1 . Males females 18 55 year age . 2 . History perennial allergic rhinitis . 3 . Positive skin test dust mite , dog , cat indoor mold antigen . 4 . And combine nasal morning even score â‰¥4 nasal congestion day precede entry 1 . Physical sign symptom suggestive renal , hepatic cardiovascular disease . 2 . Pregnant lactating woman . 3 . Subjects treat systemic steroid previous 30 day . 4 . Subjects treat topical ( inhaled , intranasal intraocular ) steroid , Nasalcrom Opticrom previous 30 day . 5 . Subjects treat oral antihistamine/decongestants previous seven day . 6 . Subjects treat topical ( intranasal intraocular ) antihistamine/decongestants previous 3 day . 7 . Subjects treat immunotherapy escalate dose . 8 . Subjects chronic antiasthma medication . 9 . Subjects polyps nose significantly displace septum . 10 . Upper respiratory infection within 14 day study start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>